诉讼案件概述 - 诉讼针对Avis Budget Group公司涉嫌证券欺诈行为 涉及时间范围为2024年2月16日至2025年2月10日 [1] - 诉讼旨在为受影响的投资者挽回损失 投资者可通过指定链接或联系方式参与 [1][3] 指控内容 - 公司被指控在2024年第四季度加速车队轮换计划 导致美洲部门车辆使用寿命缩短 可回收价值降低 [2] - 上述行为导致公司需确认数十亿美元减值损失 并对财务业绩产生重大负面影响 [2] - 公司财务和业务前景被夸大 被告方公开声明存在重大虚假和误导性内容 [2] 诉讼程序 - 受影响投资者需在2025年6月24日前申请成为首席原告 但参与赔偿无需担任首席原告角色 [3] - 集体诉讼成员可能获得补偿且无需支付自付费用 [3] 律所背景 - Levi & Korsinsky律所在过去20年为股东挽回数亿美元损失 拥有70多名员工的专业团队 [4] - 该律所连续七年被ISS证券集体诉讼服务评为美国顶级证券诉讼律所之一 [4]

NEW YORK, May 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Avis Budget Group, Inc. (NASDAQ: CAR) between February 16, 2024 and February 10, 2025, both dates inclusive (the “Class Period”), of the important June 24, 2025 lead plaintiff deadline. SO WHAT: If you purchased Avis Budget securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

核心观点 - CARsgen Therapeutics宣布其CAR T细胞疗法satricabtagene autoleucel（satri-cel）在晚期胃癌/胃食管结合部癌（G/GEJC）的II期临床试验中取得显著疗效，与标准治疗相比显著延长无进展生存期（PFS）和总生存期（OS）[1][9] - satri-cel在CLDN18.2阳性G/GEJC患者中显示出临床意义的生存获益和可控的安全性，可能成为新的标准治疗方案[9] - 这是首个在实体瘤中进行的CAR-T疗法确证性随机对照试验，具有里程碑意义[9] 临床试验设计 - 开放标签、多中心、随机对照试验（RCT），在中国进行，比较satri-cel与标准治疗（SOC）在CLDN18.2阳性、至少两线治疗失败的晚期G/GEJC患者中的疗效和安全性[2] - 主要终点为独立评审委员会（IRC）评估的无进展生存期（PFS），关键次要终点为总生存期（OS）[2] - 患者按2:1比例随机分配至satri-cel组或医生选择治疗（TPC）组，satri-cel组接受最多3次250×10^6细胞的输注，TPC组接受标准治疗药物[3] 患者基线特征 - 2022年3月29日至2024年8月16日期间，共156例患者随机分组（satri-cel组104例，TPC组52例）[4] - 两组中位既往系统治疗线数为2，26.9% vs 19.2%患者接受≥3线治疗，71.2% vs 65.4%为Lauren弥漫/混合型，69.2% vs 59.6%有腹膜转移[4] 疗效结果 - 在意向治疗（ITT）人群中，satri-cel组中位PFS显著延长（3.25个月 vs 1.77个月，HR 0.366，疾病进展或死亡风险降低63%）[5] - satri-cel组显示出OS获益趋势（中位OS 7.92个月 vs 5.49个月，HR 0.693，死亡风险降低30%以上）[5] - 在改良ITT（mITT）人群中，satri-cel组中位PFS为4.37个月 vs 1.84个月（HR 0.304，风险降低70%），中位OS为8.61个月 vs 5.49个月（HR 0.601，风险降低40%）[6] 后续治疗分析 - 20例TPC组患者后续接受satri-cel治疗，中位OS达9.20个月[7] - 所有108例接受satri-cel输注的患者中位OS为9.17个月，而未接受satri-cel的28例TPC组患者中位OS仅3.98个月（HR 0.288）[7] 安全性 - satri-cel安全性良好，仅报告4例3级细胞因子释放综合征（CRS），无4-5级CRS事件，未报告免疫效应细胞相关神经毒性综合征（ICANS）[8] 产品管线与监管进展 - satri-cel是全球潜在首款靶向Claudin18.2的自体CAR T细胞产品，主要开发用于G/GEJA和胰腺癌[10] - 2025年3月获中国国家药监局药品审评中心突破性治疗认定，2022年1月获美国FDA再生医学先进疗法认定，2020年9月获FDA孤儿药认定[10] 公司概况 - CARsgen是一家专注于创新CAR T细胞疗法的生物制药公司，覆盖血液肿瘤、实体瘤和自身免疫疾病领域[11] - 拥有从靶点发现到商业化生产的端到端研发能力，致力于解决现有CAR T疗法的安全性、实体瘤疗效和治疗成本等挑战[11]

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Avis Budget Group, Inc. (NASDAQ: CAR) between February 16, 2024 and February 10, 2025, both dates inclusive (the “Class Period”), of the important June 24, 2025 lead plaintiff deadline. SO WHAT: If you purchased Avis Budget securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Avis Budget Group, Inc. ("Avis Budget" or the "Company") (NASDAQ: CAR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Avis Budget investors who were adversely affected by alleged securities fraud between February 16, 2024 and February 10, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/avis-budge ...

NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Avis Budget Group, Inc. (NASDAQ: CAR). Shareholders who purchased shares of CAR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/avis-budget-loss-submission-form/?id=149363&from=3 CLASS PERIOD: February 16, ...

NEW YORK, May 20, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Avis Budget Group, Inc. ("Avis Budget" or the "Company") (NASDAQ: CAR) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Avis Budget investors who were adversely affected by alleged securities fraud between February 16, 2024 and February 10, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/avis-budget-laws ...

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Avis Budget Group, Inc. ("Avis Budget" or the "Company") (NASDAQ: CAR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Avis Budget investors who were adversely affected by alleged securities fraud between February 16, 2024 and February 10, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/avis-budge ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Avis To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Avis between February 16, 2024 and February 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- Faruqi & F ...

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Avis Budget Group, Inc. ("Avis Budget" or the "Company") (NASDAQ: CAR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Avis Budget investors who were adversely affected by alleged securities fraud between February 16, 2024 and February 10, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/avis-budge ...